Akèy › Neoplazmi myeloproliferatif
Etid klinik pou Neoplazmi myeloproliferatif ap rekrite nan Etazini
50 etid pou Neoplazmi myeloproliferatif ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX16 etid
- New York City, NY15 etid
- Boston, MA14 etid
- Miami, FL10 etid
- Milwaukee, WI10 etid
- Baldwin Park, CA9 etid
- Seattle, WA9 etid
- Chicago, IL9 etid
- Durham, NC9 etid
- Cleveland, OH8 etid
- St. Louis, MO8 etid
- Birmingham, AL8 etid
- Philadelphia, PA8 etid
- Portland, OR8 etid
- Columbus, OH8 etid
- Tampa, FL8 etid
- Salt Lake City, UT8 etid
- Baltimore, MD7 etid
- Mountain View, CA7 etid
- Kansas City, MO7 etid
- Winston-Salem, NC7 etid
- Atlanta, GA7 etid
- Nashville, TN6 etid
- Irvine, CA6 etid
- Los Angeles, CA6 etid
- Ann Arbor, MI6 etid
- Jacksonville, FL6 etid
- Charlotte, NC6 etid
- Phoenix, AZ6 etid
- Rochester, MN5 etid
- San Francisco, CA5 etid
- Edison, NJ5 etid
- Pittsburgh, PA5 etid
- Washington, DC5 etid
- Sacramento, CA5 etid
- Charlottesville, VA5 etid
- Omaha, NE5 etid
- Minneapolis, MN5 etid
- Aurora, CO4 etid
- Denver, CO4 etid
Pa eta
- Alabama8 etid
- Arizona8 etid
- Arkansas4 etid
- Ayiti3 etid
- Colorado6 etid
- Connecticut5 etid
- Florid13 etid
- Georgia9 etid
- Idaho4 etid
- Illinois9 etid
- Indiana4 etid
- Iowa4 etid
- Kalifòni16 etid
- Kansas6 etid
- Kentucky3 etid
- Lwizyàn4 etid
- Main4 etid
- Maryland8 etid
- Massachusetts15 etid
- Michigan8 etid
- Minnesota8 etid
- Mississippi4 etid
- Missouri8 etid
- Montana3 etid
- Nebraska5 etid
- Nevada3 etid
- New Jersey5 etid
- New Mexico4 etid
- New York15 etid
- North Carolina13 etid
- Ohio11 etid
- Oklahoma5 etid
- Oregon8 etid
- Pennsylvania10 etid
- Rhode Island4 etid
- South Carolina5 etid
- Tennessee8 etid
- Texas18 etid
- Utah8 etid
- Vermont3 etid
- Virginia6 etid
- Washington9 etid
- Wisconsin10 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Ap rekriteFaz 1/2
Laj 12 a 120 · Tout sèks · Mizajou Sep 30, 2026 · NCT06303193A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06661915MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT05320198Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
Laj 18 a 59 · Tout sèks · Mizajou Sep 22, 2026 · NCT05554406A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07469891Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Ap rekriteFaz 1
Laj 1 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT03630991Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT04282187(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT04996875Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT03471260Cord Blood Transplant in Adults With Blood Cancers
Ap rekriteFaz 2
Laj 21 a 65 · Tout sèks · Mizajou Sep 11, 2026 · NCT05884333Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT06291987Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT06523556CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT04493164Project: Every Child for Younger Patients With Cancer
Ap rekriteEtid obsèvasyon
Jiska laj 25 · Tout sèks · Mizajou Aug 25, 2026 · NCT02402244Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
Ap rekrite
Laj 19 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04898790Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07565220A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07008118Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT07249840A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Jul 28, 2026 · NCT07020533Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Ap rekriteFaz 2
6 Months – 65 Years · Tout sèks · Mizajou Jul 22, 2026 · NCT06013423Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT07441694Evaluation of the Pathobiology of CALR-mutated MPN Cells
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT06480591Asciminib Roll-over Study
Ap rekriteFaz 4
Laj 7 a 100 · Tout sèks · Mizajou Jul 6, 2026 · NCT04877522Allo HSCT Using RIC and PTCy for Hematological Diseases
Ap rekriteFaz 2
Jiska laj 75 · Tout sèks · Mizajou Jul 6, 2026 · NCT05805605Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.